Milestone Pharmaceuticals (MIST) Free Cash Flow (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Free Cash Flow for 9 consecutive years, with -$22.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow fell 80.81% year-over-year to -$22.7 million; the trailing twelve-month figure through Jun 2026 stood at -$61.6 million (down 52.51% YoY), and the FY2025 full-year result was -$49.3 million, down 70.85% from the prior year.
• Free Cash Flow retreated to -$22.7 million in Q2 2026 per MIST's latest filing, from -$16.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$6.1 million in Q2 2024 and bottomed at -$22.7 million in Q2 2026.
• Historically, Free Cash Flow has averaged -$12.0 million across 5 years, with a median of -$12.4 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 1487.68% in 2022, then soared 42.87% in 2024.
• Over 5 years, Free Cash Flow stood at -$13.0 million in 2022, then grew by 24.24% to -$9.8 million in 2023, then soared by 30.14% to -$6.9 million in 2024, then slumped by 90.21% to -$13.1 million in 2025, then tumbled by 74.15% to -$22.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$22.7 million, -$16.1 million, and -$13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.